The Pharmaceutical Research Shared Resource provides a broad spectrum of pharmacological and pharmaceutical services essential to conduct of preclinical and clinical research in cancer biology, drug discovery, drug evaluation, and related areas by members of the Duke Cancer Institute (DCI). It is composed of two services: the Investigational Chemotherapy Service (ICS) and the Pharmacokinetics/ Pharmacodynamics (PK/PD) service. The ICS prepares investigational drug products, maintains drug accountability records and investigational drug inventories according to FDA and CTEP guidelines, provides design consultation, professional staff education, and implementation services for clinical research studies. Managed by and integral with the Department of Pharmacy, the ICS is staffed by a clinical pharmacist, a clinical research coordinator and clinical research specialist. ICS, which has provided services to the DCI for over 20 years, is located in the new Duke Cancer Center building adjacent to the Department of Pharmacy Cancer Center Infusion Pharmacy. PK/PD services are provided by the PK/PD Core which is located in a custom-designed analytical laboratory area contiguous with the new Duke Cancer Center building. It is managed by DCI and is equipped with state-of-the-art analytical and computational equipment. PK/PD services are based on the following primary technologies: liquid chromatography - tandem-mass spectroscopy (LC- MS/MS), HPLC-fluorescence, HPLC-UV/vis, and fluorescence/UV/vis plate readers for ELISA assays. These technologies cover 99% of any need on campus for small molecule (drugs, drug-metabolites, metabolome, biomarkers) analysis in cell culture, bodily fluids, or tissues. The Shared Resource provides cost-effective access to DCI members for key early activities related to drug development: investigational drug preparation/dispensing and PK/PD testing. The ICS is supporting more than 200 active clinical studies currently, and the PK/PD service has served 35 investigators' laboratories since 2009, including 24 DCI members' labs (representing seven of the nine CCSG-recognized Research Programs); 15 (63%) of the DCI users have peer-reviewed funding. Since 2009, Duke investigators have published 75 papers utilizing data from studies managed by the ICS and 63 papers (36 from clinical research) utilizing PK/PD data obtained through the Shared Resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-44
Application #
9404304
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784

Showing the most recent 10 out of 513 publications